Acute myeloid leukaemia after treatment with (90)Y-ibritumomab tiuxetan for follicular lymphoma.
We report here a patient with relapsed follicular lymphoma who developed secondary acute myeloid leukaemia 15 months after radioimmunotherapy (RIT) with (90)Y-ibritumomab tiuxetan, the fifth described case to date. We review the literature for the potential causal relationship between RIT and secondary myelodysplastic syndromes/acute myeloid leukaemia.
Focosi
Daniele
D
Division of Hematology, Department of Oncology, Transplantations and New Technologies in Medicine, University of Pisa, Italy. focosi@icgeb.org
Cecconi
Nadia
N
Boni
Giuseppe
G
Orciuolo
Enrico
E
Galimberti
Sara
S
Petrini
Mario
M
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000209:etiology*; D008224:Lymphoma, Follicular / Q000532:radiotherapy*; D008875:Middle Aged; D016609:Neoplasms, Second Primary / Q000209:etiology*; D016499:Radioimmunotherapy; D015021:Yttrium Radioisotopes / Q000627:therapeutic use*
D000911:Antibodies, Monoclonal; D015021:Yttrium Radioisotopes; C422802:ibritumomab tiuxetan